If Cigna, a company that runs insurance for millions, doesnt see these meds as affordable for its own workforce, you know the landscape is shifting
Tirzepatide is administered as a once-weekly subcutaneous injection, starting at 2.5 mg for 4 weeks (an initiation dose), then typically increasing to 5 mg, with possible further increases to 7.5, 10, 12.5, or 15 mg based on clinical response and tolerability
For example, if a patients blood pressure or blood sugar levels improve during treatment with a GLP-1 agonist, they can go back to where they were when they stop, she said
The staff has been very responsive
this local reaction typically resolves on its own within a day or two